Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016 - Product Image

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016

  • ID: 3946489
  • Report
  • 73 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AgeneBio Inc.
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • MORE
Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline landscape.

Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. Alzheimer's is a type of dementia. Symptoms include depression, social withdrawal, mood swings, irritability and aggressiveness and loss of inhibitions. Risk factors include age, family history and mild cognitive impairment. Treatment includes cholinesterase inhibitors and healthy life style.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 6, 2 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Dementia Associated With Alzheimer's Disease.

Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AgeneBio Inc.
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Dementia Associated With Alzheimer's Disease Overview

Therapeutics Development

Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview

Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis

Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies

Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes

Dementia Associated With Alzheimer's Disease - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Dementia Associated With Alzheimer's Disease - Products under Development by Companies

Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes

Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development

Adamas Pharmaceuticals, Inc.

AgeneBio Inc.

Amarantus Bioscience Holdings, Inc.

Boehringer Ingelheim GmbH

Chase Pharmaceuticals Corporation

Eisai Co., Ltd.

H. Lundbeck A/S

MediPost Co., Ltd.

Dementia Associated With Alzheimer's Disease - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(donepezil hydrochloride + solifenacin succinate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-409306 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-2609 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltoprazine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gln-1062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levetiracetam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUAF-20513 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neurostem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

salicylamine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-070 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dementia Associated With Alzheimer's Disease - Dormant Projects

Dementia Associated With Alzheimer's Disease - Discontinued Products

Dementia Associated With Alzheimer's Disease - Product Development Milestones

Featured News & Press Releases

Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation

Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer’s Association International Conference

Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering & Investment Forum

Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website

Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression

Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference

Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer’s Disease

Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia

Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer’s Dementia

Jan 28, 2015: AgeneBio Receives Grant from Alzheimer’s Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer’s Dementia

May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories

May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016

Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Comparative Analysis by Unknown Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016

Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2016

Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016

Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Adamas Pharmaceuticals, Inc.
AgeneBio Inc.
Amarantus Bioscience Holdings, Inc.
Boehringer Ingelheim GmbH
Chase Pharmaceuticals Corporation
Eisai Co., Ltd.
H. Lundbeck A/S
MediPost Co., Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll